Literature DB >> 32713632

Revisiting prosthesis choice in mitral valve replacement in children: Durable alternatives to traditional bioprostheses.

Perry S Choi1, Lynn A Sleeper2, Minmin Lu3, Patrick Upchurch4, Christopher Baird1, Sitaram M Emani5.   

Abstract

OBJECTIVE: To determine risk factors for re-replacement and death or transplant following mitral valve replacement (MVR) in children
METHODS: This is a retrospective 26-year review of patients younger than 20 years of age undergoing MVR between 1992 and 2018 at single institution. Outcomes included freedom from re-MVR and transplant-free survival. Cox proportional hazards regression models assessed association between outcomes and potential risk factors.
RESULTS: At median age 4.2 years, 190 children underwent 290 MVR: 180 mechanical, 63 porcine, 13 pericardial, and 34 stented bovine jugular vein valves. Re-MVR occurred in 100 valves. Freedom from re-MVR at 5 and 10 years was 76% and 44%. Times to re-MVR were associated with prosthesis type (P < .001), with porcine and pericardial valves at greatest risk. Other risk factors for prosthetic failure included smaller prosthesis size and left ventricular hypoplasia. There were 9 transplants and 44 deaths. Transplant-free survival at 5 and 10 years was 81% and 76%. Prosthesis type was significantly associated with time to death/transplant in univariate analysis only (P = .021), with porcine at greater risk than mechanical. Independent risk factors for death/transplant included larger indexed geometric orifice area and longer bypass time.
CONCLUSIONS: In pediatric patients undergoing MVR, mechanical and stented bovine jugular vein valves were associated with increased durability compared with fixed-diameter bioprosthetic alternatives.
Copyright © 2020 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Melody valve; bioprosthetic; congenital heart surgery; mechanical; mitral valve replacement; prosthetic durability

Year:  2020        PMID: 32713632     DOI: 10.1016/j.jtcvs.2020.04.173

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  1 in total

1.  Commentary: The antifragility of the Melody valve.

Authors:  Christoph Haller; Osami Honjo
Journal:  JTCVS Tech       Date:  2020-10-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.